var data={"title":"Ferrous fumarate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ferrous fumarate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6190?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ferrous-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Ferrous fumarate: Drug information&quot;</a> and <a href=\"topic.htm?path=ferrous-fumarate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ferrous fumarate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170762\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ferretts [OTC];</li>\n      <li>Ferrimin 150 [OTC];</li>\n      <li>Ferrocite [OTC] [DSC];</li>\n      <li>Hemocyte [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170763\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Palafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1013905\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Iron Salt</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mineral, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1013930\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ferrous-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Ferrous fumarate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses expressed as <b>elemental</b> iron. Ferrous fumarate contains 33% elemental iron:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 8 years: 10 mg /day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 9 to 13 years: 8 mg /day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 14 to 18 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Male: 11 mg /day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Female: 15 mg /day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency, prevention:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years in areas where anemia prevalence is &gt;40%: 30 mg/day  with folic acid (WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents in areas where anemia prevalence is &gt;40%:  60 mg/day with folic acid (WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency, treatment of iron deficiency:</b> Oral: Children and Adolescents: 3 to 6 mg/kg/day in 3 divided doses (Carney 2010; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA):</b> Oral </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">19 to 50 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Males:  8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Females 18 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;50 years: 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency, prevention:</b> Oral: 60 mg once daily (Stoltzfus 1998; WHO 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency, treatment of iron deficiency:</b> Oral: 100 to 200 mg daily in 2 to 3 divided doses (Liu 2012; Stoltzfus 1998; WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> To avoid GI upset, start with a single daily dose and increase by 1 tablet/day each week or as tolerated until desired daily dose is achieved. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170746\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferretts: 325 mg (106 mg elemental iron) [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferrimin 150: Elemental iron 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferrocite: 324 mg (106 mg elemental iron) [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #5 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemocyte: 324 mg (106 mg elemental iron)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 90 mg (29.5 mg elemental iron) [DSC], 324 mg (106 mg elemental iron), Elemental iron 29 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170733\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1013935\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Do not chew or crush sustained release preparations; administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2984985\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Iron is a leading cause of fatal poisoning in children. Store out of children's reach and in child-resistant containers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1013906\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and treatment of iron deficiency anemias (OTC: FDA approved in adults; see product specific labeling for pediatric approval ages);  has also been used as supplemental therapy for patients receiving epoetin alfa  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170797\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, darkening of stools, dental discoloration, diarrhea, heartburn, nausea, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Local irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170752\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iron salts or any component of the formulation; hemochromatosis, hemolytic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170737\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the &ldquo;anemia of chronic disease&rdquo; is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820034\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Consider all iron sources when evaluating the dose of iron, including combination products, infant formulas, and liquid nutritional supplements.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299322\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170742\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13054&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Iron Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Entacapone: Iron Salts may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Salts. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron salts. Therapy with oral iron salts should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron salts. Therapy with oral iron salts should begin 5 days after the last dose of IV iron isomaltoside.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Iron Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170760\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789285\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5262763\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1013924\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serum iron: 22-184 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Total iron binding capacity: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 100-400 mcg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adults: 250-400 mcg/dL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170736\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces iron found in hemoglobin, myoglobin, and enzymes; allows the transportation of oxygen via hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170751\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response: Oral, parenteral iron salts: ~3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Reticulocytosis: 5 to 10 days; hemoglobin values increase within 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal serum iron stores, 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores. Food and achlorhydria will decrease absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: To serum transferrin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine, sweat, sloughing of intestinal mucosa, and menses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5262765\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">When treating iron deficiency anemias, treat for 3-4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Elemental Iron Content of Iron Salts</caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Iron Salt</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Elemental Iron Content</p>\n            <p style=\"text-indent:0em;\">(% of salt form)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Approximate</p>\n            <p style=\"text-indent:0em;\">Equivalent Doses</p>\n            <p style=\"text-indent:0em;\">(mg of iron salt)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Ferrous fumarate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">33</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">197</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Ferrous gluconate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">560</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Ferrous sulfate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">324</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Ferrous sulfate, exsiccated</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">217</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323149\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferrimin 150 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (120): $15.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferrocite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 mg (100): $22.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferrous Fumarate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 (106 Fe) mg (100): $35.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hemocyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 (106 Fe) mg (30): $11.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170755\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ercofer (SE);</li>\n      <li>Femarate (TH);</li>\n      <li>Feroson (BD);</li>\n      <li>Ferrate (KW, LB);</li>\n      <li>Ferraton (EC);</li>\n      <li>Ferro-Tab (AU);</li>\n      <li>Ferrobet (AT);</li>\n      <li>Ferrokapsul (DE);</li>\n      <li>Ferroklinge (BR);</li>\n      <li>Ferronat (BG, CZ);</li>\n      <li>FerroTab (NZ);</li>\n      <li>Ferrum Hausmann (BE, CH, DE, LU);</li>\n      <li>Fersaday (GB);</li>\n      <li>Ferumat (BE, LU, NL);</li>\n      <li>Ferval (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Fumafer (AE, FR, PT, QA, SA, VE);</li>\n      <li>Fumiron (DE);</li>\n      <li>Galfer (IE);</li>\n      <li>Heferol (HR);</li>\n      <li>Hema F (TW);</li>\n      <li>Hierro (AR);</li>\n      <li>Neo-Fer (NO);</li>\n      <li>Rulofer N (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, The A.S.P.E.N Pediatric Nutrition Support Core Curriculum, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 440-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States,&quot; <i>MMWR REcomm Rep</i>, 1998, 47(RR-3):1-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine, National Research Council, &quot;Iron Deficiency Anemia: Recommended Guidelines for the Prevention, Detection, and Management Among U.S. Children and Women of Childbearing Age,&quot; Washington, D.C.: The National Academies Press, 1993.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.  </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(2):109-116. Available at <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22157204\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/pubmed/22157204</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-fumarate-pediatric-drug-information/abstract-text/22157204 /pubmed\" target=\"_blank\" id=\"22157204 \">22157204 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stoltzfus RJ, Dreyfuess ML. Guidelines for the Use of Iron supplements to Prevent and Treat Iron Deficiency Anemia. International Nutritional Anemia Consultative Group (INACG), 1998. Available at: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/1-57881-020-5/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Iron Deficiency Anaemia: Assessment, Prevention, and Control.  A Guide for Programme Managers,&rdquo; 2001. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13054 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170762\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170763\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1013905\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1013930\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170746\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F170733\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1013935\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2984985\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1013906\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170797\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170752\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170737\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820034\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299322\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F170742\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F170760\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6789285\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5262763\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1013924\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170736\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F170751\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F5262765\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323149\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170755\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13054|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ferrous-fumarate-drug-information\" class=\"drug drug_general\">Ferrous fumarate: Drug information</a></li><li><a href=\"topic.htm?path=ferrous-fumarate-patient-drug-information\" class=\"drug drug_patient\">Ferrous fumarate: Patient drug information</a></li></ul></div></div>","javascript":null}